Featured Publications
A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST)
Oikonomou EK, Van Dijk D, Parise H, Suchard MA, de Lemos J, Antoniades C, Velazquez EJ, Miller EJ, Khera R. A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). European Heart Journal 2021, 42: 2536-2548. PMID: 33881513, PMCID: PMC8488385, DOI: 10.1093/eurheartj/ehab223.Peer-Reviewed Original ResearchConceptsStable chest painChest painPrimary endpointMajor adverse cardiovascular eventsNon-fatal myocardial infarctionAdverse cardiovascular eventsStudy's primary endpointCoronary artery diseaseClinical trial populationsCox regression modelParticipant-level dataSCOT-HEARTCardiovascular eventsCause mortalityHazard ratioPatients 5Artery diseaseFunctional testingPROMISE trialTrial populationMyocardial infarctionLower incidenceStudy populationPainCollected variables
2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates